IT

ITOXI Corp.

B2B platform for Ukraine-Korea trade, investment, and post-war reconstruction.

052770 | KO

Overview

Corporate Details

ISIN(s):
KR7052770005
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 427 파모소빌딩 4층, 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ITOXI Corp. is a diversified corporation, formerly known as YD Online Corp, with a history in the online and mobile game development industry. The company has expanded its business scope to include international business promotion and strategic partnership development. A key division, ITOXI UA, operates as a B2B platform facilitating cooperation, trade, and investment between Ukrainian and Korean companies. This platform offers end-to-end services including market research, partner sourcing and vetting, negotiation support, and project implementation for joint ventures and investment projects, with a particular focus on Ukraine's post-war reconstruction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Delisting Announcement
주권매매거래정지 (자본감소)
Korean 4.7 KB
2025-09-08 00:00
Share Issue/Capital Change
주요사항보고서(감자결정)
Korean 15.7 KB
2025-09-08 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.0 KB
2025-09-08 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-09-08 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(감자결정)
Korean 18.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.5 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-08-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 51.2 KB
2025-06-12 00:00
Share Issue/Capital Change
[정정명령부과][기재정정]주요사항보고서(전환사채권발행결정)
Korean 52.9 KB
2025-06-12 00:00
Share Issue/Capital Change
전환청구권행사 (제15회차)
Korean 9.6 KB
2025-06-05 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.8 KB
2025-05-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제17회차 CB)
Korean 6.1 KB
2025-05-19 00:00
Capital/Financing Update
[기재정정]주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 41.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all ITOXI Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ITOXI Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ITOXI Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.